Suh Jungyo, Jeong In Gab, Jeon Hwang Gyun, Jeong Chang Wook, Lee Sangchul, Jeon Seong Soo, Byun Seok Soo, Kwak Cheol, Ahn Hanjong
Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
J Cancer Res Clin Oncol. 2023 May;149(5):1951-1960. doi: 10.1007/s00432-022-04243-3. Epub 2022 Aug 9.
This study aimed to compare the long-term oncological outcomes of robot-assisted radical prostatectomy (RARP) vs. open radical prostatectomy (ORP) in pathologically proven prostate cancer with seminal vesicle invasion (SVI).
We performed a cohort study involving men who underwent radical prostatectomy for prostate cancer with SVI. We adjusted the confounders for RARP versus open surgery using the stabilized inverted probability of treatment weighting. Multivariable survival regression analysis was used to compare the treatment effect of RARP vs. ORP on biochemical recurrence (BCR) and clinical progression (CP).
Between January 2000 and December 2012, 272 of 510 men (53.3%) underwent RARP at four tertiary hospitals in Korea. The median follow-up in the entire cohort was 75.7 months (interquartile range, 58.9-96.6 months). Among 389 BCR events, 205 (75.4%) and 184 (77.3%) occurred in the robot-assisted and open groups, respectively. The 5-year BCR-free survival was 22.2% and 20.5% among men who underwent RARP and ORP, respectively (hazard ratio (HR) 0.90; 95% confidence interval (CI), 0.73-1.10; P = 0.29 by the log-rank test). Ninety-nine patients experienced CP (55 and 44 in the RARP and open groups, respectively), representing Kaplan-Meier estimated 5-year event-free rates of 82.1% and 86.1% in the RARP and open groups, respectively, (HR 1.20; 95% CI 0.80-1.79; P = 0.39).
The long-term outcomes of RARP for prostate cancer with SVI were comparable to those of open surgery in this large multi-institutional study. However, this result should be confirmed by well-designed prospective randomized controlled trials.
本研究旨在比较机器人辅助根治性前列腺切除术(RARP)与开放性根治性前列腺切除术(ORP)对病理证实有精囊侵犯(SVI)的前列腺癌患者的长期肿瘤学结局。
我们进行了一项队列研究,纳入了因前列腺癌合并SVI而接受根治性前列腺切除术的男性患者。我们使用稳定的治疗权重逆概率对RARP与开放手术的混杂因素进行了调整。采用多变量生存回归分析来比较RARP与ORP对生化复发(BCR)和临床进展(CP)的治疗效果。
2000年1月至2012年12月期间,韩国四家三级医院的510名男性患者中有272名(53.3%)接受了RARP。整个队列的中位随访时间为75.7个月(四分位间距,58.9 - 96.6个月)。在389例BCR事件中,机器人辅助组和开放组分别有205例(75.4%)和184例(77.3%)。接受RARP和ORP的男性患者5年无BCR生存率分别为22.2%和20.5%(风险比(HR)0.90;95%置信区间(CI),0.73 - 1.10;对数秩检验P = 0.29)。99例患者出现CP(RARP组和开放组分别为55例和44例),RARP组和开放组的Kaplan-Meier估计5年无事件发生率分别为82.1%和86.1%(HR 1.20;95% CI 0.80 - 1.79;P = 0.39)。
在这项大型多机构研究中,RARP治疗合并SVI的前列腺癌的长期结局与开放手术相当。然而,这一结果应通过精心设计的前瞻性随机对照试验来证实。